{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=11&q=advanced+solid+tumors",
    "query": {
      "q": "advanced solid tumors",
      "condition": "Cancer",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 5924,
    "total_pages": 593,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=12&q=advanced+solid+tumors&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=10&q=advanced+solid+tumors&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T02:20:04.938Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05069935",
      "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor, Adult"
      ],
      "interventions": [
        {
          "name": "FT538",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Monoclonal antibody - Dose Escalation",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Monoclonal antibody - Dose Expansion",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Fate Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2021-10-15",
      "completion_date": "2023-08-11",
      "has_results": false,
      "last_update_posted_date": "2023-09-21",
      "last_synced_at": "2026-10-14T02:20:04.938Z",
      "location_count": 4,
      "location_summary": "Hackensack, New Jersey • Nashville, Tennessee • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05069935"
    },
    {
      "nct_id": "NCT00471276",
      "title": "Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "sunitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 83,
      "start_date": "2007-08",
      "completion_date": "2010-06",
      "has_results": true,
      "last_update_posted_date": "2011-07-25",
      "last_synced_at": "2026-10-14T02:20:04.938Z",
      "location_count": 31,
      "location_summary": "Bakersfield, California • Burbank, California • Fountain Valley, California + 24 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Hawthorne",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00471276"
    },
    {
      "nct_id": "NCT00417976",
      "title": "Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Infusional 5-Fluorouracil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tony Bekaii-Saab",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2006-12",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2015-10-01",
      "last_synced_at": "2026-10-14T02:20:04.938Z",
      "location_count": 2,
      "location_summary": "Ann Arbor, Michigan • Columbus, Ohio",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00417976"
    },
    {
      "nct_id": "NCT04345913",
      "title": "Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Metastatic Triple-Negative Breast Carcinoma",
        "Unresectable Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Copanlisib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Eribulin Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2021-03-01",
      "completion_date": "2027-05-31",
      "has_results": true,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-10-14T02:20:04.938Z",
      "location_count": 43,
      "location_summary": "Sacramento, California • Derby, Connecticut • Fairfield, Connecticut + 34 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Derby",
          "state": "Connecticut"
        },
        {
          "city": "Fairfield",
          "state": "Connecticut"
        },
        {
          "city": "Glastonbury",
          "state": "Connecticut"
        },
        {
          "city": "Greenwich",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04345913"
    },
    {
      "nct_id": "NCT07612176",
      "title": "A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Locally Advanced (Unresectable) or Metastatic Solid Tumors"
      ],
      "interventions": [
        {
          "name": "NEOK001",
          "type": "DRUG"
        },
        {
          "name": "NEOK001 RDE",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NEOK Bio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 155,
      "start_date": "2026-04-21",
      "completion_date": "2029-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-14T02:20:04.938Z",
      "location_count": 9,
      "location_summary": "New York, New York • Nashville, Tennessee • Austin, Texas + 4 more",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07612176"
    },
    {
      "nct_id": "NCT05110781",
      "title": "Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck",
        "Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck",
        "Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2021-12-07",
      "completion_date": "2023-04-18",
      "has_results": true,
      "last_update_posted_date": "2026-06-05",
      "last_synced_at": "2026-10-14T02:20:04.938Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05110781"
    },
    {
      "nct_id": "NCT02795819",
      "title": "Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Cell Carcinoma",
        "Soft Tissue Sarcoma",
        "Metastatic Disease"
      ],
      "interventions": [
        {
          "name": "AR-42",
          "type": "DRUG"
        },
        {
          "name": "Pazopanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2016-07-08",
      "completion_date": "2019-03-14",
      "has_results": true,
      "last_update_posted_date": "2019-10-24",
      "last_synced_at": "2026-10-14T02:20:04.938Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02795819"
    },
    {
      "nct_id": "NCT03283696",
      "title": "A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "Olaratumab",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2017-10-18",
      "completion_date": "2019-08-25",
      "has_results": true,
      "last_update_posted_date": "2020-09-10",
      "last_synced_at": "2026-10-14T02:20:04.938Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Houston, Texas",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03283696"
    },
    {
      "nct_id": "NCT05639751",
      "title": "PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Metastatic Solid Tumor",
        "Non-small Cell Lung Cancers",
        "SMARCA4 Gene Mutation"
      ],
      "interventions": [
        {
          "name": "PRT3789",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Prelude Therapeutics Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 135,
      "start_date": "2023-05-02",
      "completion_date": "2025-10-01",
      "has_results": false,
      "last_update_posted_date": "2025-10-16",
      "last_synced_at": "2026-10-14T02:20:04.938Z",
      "location_count": 20,
      "location_summary": "Sacramento, California • Santa Monica, California • New Haven, Connecticut + 13 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Celebration",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05639751"
    },
    {
      "nct_id": "NCT02109653",
      "title": "Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "LGX818",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Array Biopharma, now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2015-06",
      "completion_date": "2017-11",
      "has_results": false,
      "last_update_posted_date": "2020-11-13",
      "last_synced_at": "2026-10-14T02:20:04.938Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02109653"
    }
  ]
}